Legend Biotech (LEGN)

• Market cap: $6.01B
• 1 day: 0.00%
• 5 days: -6.05%
• 1 month: -21.28%
• 3 months: -32.90%
• 6 months: -29.84%
• Year to date: -5.64%
• 1 year: -44.57%
• 5 years: -11.43%
• 10 years: -11.43%

About: Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Employees: 1,800

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

175% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 16

15% more funds holding

Funds holding: 177 [Q2] → 204 (+27) [Q3]

9% more capital invested

Capital invested by funds: $4.09B [Q2] → $4.47B (+$372M) [Q3]

0.21% less ownership

Funds ownership: 25.41% [Q2] → 25.19% (-0.21%) [Q3]

1% less repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 69

14% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 6 (-1) [Q3]

49% less call options, than puts

Call options by funds: $12.2M | Put options by funds: $24M

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $73 123% upside
• Avg. target: $80 144% upside
• High target: $86 162% upside

4 analyst ratings

• positive: 4 100%
• neutral: 0 0%
• negative: 0 0%

Piper Sandler Edward Tenthoff 27% 1-year accuracy 12 / 45 met price target	138% upside $78	Overweight Reiterated	30 Dec 2024
HC Wainwright & Co. Mitchell Kapoor 27% 1-year accuracy 45 / 164 met price target	123% upside $73	Buy Reiterated	10 Dec 2024
Cantor Fitzgerald Rick Bienkowski 14% 1-year accuracy 1 / 7 met price target	153% upside $83	Overweight Reiterated	9 Dec 2024
RBC Capital Leonid Timashev 39% 1-year accuracy 17 / 44 met price target	162% upside $86	Outperform Reiterated	9 Dec 2024